Device Trial Radar · NCT00763360
To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
Last checked: Nov 20, 2026Latest source record: Jan 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
May 2008
Primary completion
Sep 2010
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Who can join
- All sexes, from 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.
Conditions
- Cataract
Interventions
DisCoVisc®Device
Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
HealonDrug
Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
Amvisc PlusDrug
Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endothelial Cell Count Change From BaselineTime frame: one month
- Investigator Reported Space MaintenanceTime frame: During surgical procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alcon Call Center
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.